Edition:
India

Chromadex Corp (CDXC.OQ)

CDXC.OQ on NASDAQ Stock Exchange Capital Market

4.42USD
19 Jul 2018
Change (% chg)

-- (--)
Prev Close
$4.42
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
100,262
52-wk High
$7.24
52-wk Low
$2.86

Chart for

About

Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address... (more)

Overall

Beta: 1.13
Market Cap(Mil.): $196.82
Shares Outstanding(Mil.): 46.09
Dividend: --
Yield (%): --

Financials

BRIEF-Chromadex Corp Appoints Rob Fried as Chief Executive Officer

* CHROMADEX APPOINTS FRANK JAKSCH AS EXECUTIVE CHAIRMAN, ROB FRIED AS CHIEF EXECUTIVE OFFICER AND KURT GUSTAFSON AS LEAD DIRECTOR

24 Apr 2018

BRIEF-Chromadex Corporation Q4 Loss Per Share $0.17

* Q4 REPORTED LOSS FROM CONTINUING OPERATIONS NEGATIVELY IMPACTED BY NON-CASH CHARGE OF $3.4 MILLION RELATED TO STOCK-BASED COMPENSATION

09 Mar 2018

BRIEF-Chromadex Chairman Stephen Allen Will Retire From The Board

* CHROMADEX CHAIRMAN STEPHEN ALLEN WILL RETIRE FROM BOARD OF DIRECTORS

17 Feb 2018

BRIEF-ChromaDex Corp Sees Q4 2017 Revenue About $7.5 Mln

* AN OPERATING LOSS FOR Q4 OF 2017 IS EXPECTED TO BE IN A RANGE OF $8.5 MILLION TO $9.5 MILLION

12 Feb 2018

BRIEF-Chromadex - Patent Trial And Appeal Board Of U.S. Patent And Trademark Office Denied Elysium Health's Request To Invalidate U.S. Patent

* CHROMADEX - PATENT TRIAL AND APPEAL BOARD OF U.S. PATENT AND TRADEMARK OFFICE DENIED ELYSIUM HEALTH INC.'S REQUEST TO INVALIDATE U.S. PATENT

22 Jan 2018

Earnings vs. Estimates